Evidence map›Paper›PMID 42482409›Full record

ArticleCancer2026

Results of second-line therapy in adult Philadelphia chromosome-positive acute lymphoblastic leukemia.

Hagop Kantarjian, Wei-Ying Jen, Eitan Kugler, Rebecca Garris, Sherry Pierce, Nitin Jain, Nicholas J Short, Issa Khouri, Sanam Loghavi, Fadi G Haddad and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Hagop KantarjianDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID https://orcid.org/0000-0002-1908-3307
Wei-Ying JenDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID https://orcid.org/0000-0002-9339-3362
Eitan KuglerDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID https://orcid.org/0009-0005-1539-1766
Rebecca GarrisDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Sherry PierceDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Nitin JainDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Nicholas J ShortDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID https://orcid.org/0000-0002-2983-2738
Issa KhouriDepartment of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID https://orcid.org/0000-0003-2473-911X
Sanam LoghaviDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Fadi G HaddadDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID https://orcid.org/0000-0002-9702-8485
Farhad RavandiDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Elias JabbourDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID https://orcid.org/0000-0003-4465-6119

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI DIANE BODURKA · 1985 to 2026
$290.8M
NCI NIH HHS P30 CA016672
6 · The paper itself

Abstract

backgroundThe approval of the BCR::ABL tyrosine kinase inhibitors (TKIs) and blinatumomab have improved outcomes in Ph-positive B-acute lymphoblastic leukemia (ALL). However, patients still relapse, and their outcomes in the TKI era have yet to be defined.

methodsPatients with relapsed/primary refractory Philadelphia chromosome (pH)-positive B-ALL ≥16 years old treated in first salvage from 1992 to 2025 were analyzed.

resultsA total of 165 patients (median age, 48; range, 17-78 years) were analyzed. The overall complete remission (CR) rate was 80%. By multivariate analysis, only the use of TKIs was associated with a significant benefit for achieving CR. The median overall survival (OS) was 15 months. The 3-year OS rate was 31%. The 3-year OS rate was 57% with third-generation TKI combinations, 38% with second-generation TKI combinations, 8% with imatinib combinations, and 0% without TKIs. By multivariate analysis, three variables were independently predictive of survival: TKI-based therapy (hazard ratio [HR], 0.10-0.49; p values all <.001 for each TKI vs. no TKI), blinatumomab-based therapy (HR, 0.36; p = .0058), and white blood cell ≥50 × 10

conclusionsThis study establishes a modern expectation of outcome of Ph-positive B-cell ALL treated in salvage 1. Third-generation TKI plus blinatumomab combinations should be given consideration in this setting.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsPrecursor Cell Lymphoblastic Leukemia-LymphomaProtein Kinase InhibitorsAdolescentAdultAgedAntibodies, BispecificFemaleHumansImatinib MesylateMaleMiddle AgedPhiladelphia ChromosomeRemission InductionRetrospective StudiesSalvage TherapyAntibodies, BispecificblinatumomabImatinib MesylateProtein Kinase InhibitorsALL salvage therapyblinatumomabCARTinotuzumab

Identifiers

PMID42482409
PMCPMC13389346

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.